Cyclo Therapeutics Inc. (CYTH)
0.72
-0.00 (-0.08%)
At close: Mar 25, 2025, 3:59 PM
-0.08% (1D)
| Bid | 0.68 |
| Market Cap | 23.59M |
| Revenue (ttm) | 992.16K |
| Net Income (ttm) | -28.26M |
| EPS (ttm) | -0.9 |
| PE Ratio (ttm) | -0.8 |
| Forward PE | -1.2 |
| Analyst | Hold |
| Ask | 0.72 |
| Volume | 186,806 |
| Avg. Volume (20D) | 1,611,870 |
| Open | 0.72 |
| Previous Close | 0.72 |
| Day's Range | 0.72 - 0.72 |
| 52-Week Range | 0.55 - 1.79 |
| Beta | -0.57 |
About CYTH
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, n...
Full Company ProfileAnalyst Forecast
According to 3 analyst ratings, the average rating for CYTH stock is "Hold." The 12-month stock price forecast is $0.95, which is an increase of 31.83% from the latest price.
Stock ForecastsNext Earnings Release
Cyclo Therapeutics Inc. is scheduled to release its earnings on Apr 15, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
+54.55%
Cyclo Therapeutics shares are trading higher after...
Unlock content with
Pro Subscription
7 months ago
-26.98%
Cyclo Therapeutics shares are trading lower after the company announced it agreed to merge with Rafael Holdings.
